Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Drug Eruptions
  • Molecular Targeted Therapy
  • Neoplasms

abstract

  • A substantial proportion of drug-related dermatologic AEs occur after the traditional dose-limiting toxicity monitoring period of phase 1 clinical trials. Future designs should account for late toxicities. Cancer 2016. © 2016 American Cancer Society.

publication date

  • January 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5479632

Digital Object Identifier (DOI)

  • 10.1002/cncr.29918

PubMed ID

  • 26916138

Additional Document Info